AFFX Affymetrix, Inc.

Affymetrix Inc. (AFFX) said it won clearance from the U.S. Food and Drug Administration for the addition of new gene expression reagents as accessories to its genetic analysis tools.

Shares were up 6.4% at $6.55 in recent premarket trading. The stock through Friday's close is up 22% this year.

The company, whose products are used by pharmaceutical, diagnostic and biotechnology companies, is aiming to generate at least a quarter of its 2011 revenue from new markets, including cytogenetics and cancer.

Affymetrix in April swung to a small first-quarter profit on lower expenses, though revenue declined more than Wall Street expected.

-By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com